메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 23, Issue 30, 2005, Pages 7738-7740
Modern treatment of lung cancer: Case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma
Author keywords

[No Author keywords available]
Indexed keywords

CARBOPLATIN; ERLOTINIB; GEFITINIB; PACLITAXEL; PEMETREXED; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;
EID: 32944470677     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.4471     Document Type: Article
Times cited : (38)
References (7)
  • 1
    • 12144287534 scopus 로고    scopus 로고
    • United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets
    • Cohen MH, Williams GA, Sridhara R, et al: United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10:1212-1218, 2004
    • (2004) Clin Cancer Res , vol.10 , pp. 1212-1218
    • Cohen, M.H.1    Williams, G.A.2    Sridhara, R.3
  • 2
    • 0012381722 scopus 로고    scopus 로고
    • Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer
    • Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21:2237-2246, 2003
    • (2003) J Clin Oncol , vol.21 , pp. 2237-2246
    • Fukuoka, M.1    Yano, S.2    Giaccone, G.3
  • 3
    • 0142055937 scopus 로고    scopus 로고
    • Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer
    • Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290:2149-2158, 2003
    • (2003) JAMA , vol.290 , pp. 2149-2158
    • Kris, M.G.1    Natale, R.B.2    Herbst, R.S.3
  • 4
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd FA, Pereira JR, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Pereira, J.R.2    Ciuleanu, T.3
  • 5
    • 25144488564 scopus 로고    scopus 로고
    • Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen
    • Johnson JR, Cohen M, Sridhara R, et al: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 11:6414-6421, 2005
    • (2005) Clin Cancer Res , vol.11 , pp. 6414-6421
    • Johnson, J.R.1    Cohen, M.2    Sridhara, R.3
  • 6
    • 33847090869 scopus 로고    scopus 로고
    • Oncology Drug Advisory Committee Meeting, March 4
    • Oncology Drug Advisory Committee Meeting, March 4, 2005
    • (2005)
  • 7
    • 21644486065 scopus 로고    scopus 로고
    • Results of a phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced non-small-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens
    • Thatcher N, Chang A, Parikh P, et al: Results of a phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced non-small-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens. Proc Am Assoc Cancer Res 2005; Late Breaking Session:LB-6
    • Proc Am Assoc Cancer Res 2005; Late Breaking Session:LB-6
    • Thatcher, N.1    Chang, A.2    Parikh, P.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.